Market Research Report
Avascular Necrosis Market - Size, Share, Trends, and Forecast to 2026
|Published by||Coherent Market Insights||Product code||738726|
|Published||Content info||147 Pages
Delivery time: 2-3 business days
|Avascular Necrosis Market - Size, Share, Trends, and Forecast to 2026|
|Published: October 10, 2018||Content info: 147 Pages||
Avascular necrosis (AVN), also called osteonecrosis, ischemic bone necrosis, or aseptic necrosis, is a condition that occurs due to loss of blood flow to the bone. The condition mostly occurs in the hip however, other common sites include ankle, knee, and shoulder. Individuals between the age of 20 and 50 years are more susceptible to avascular necrosis. Most cases of avascular necrosis occur due to an underlying health problem or injury. Moreover, factors such as increased intake of corticosteroids and alcohol may cause fatty substances to build in the blood vessels and decrease the blood supply to the bones, eventually causing avascular necrosis. Treatment for this condition depends on a number of factors, including age, disease stage, location, and amount of bone damage.
Growth of avascular necrosis market is primarily driven by factors such as increasing incidence of avascular necrosis, high demand for non-invasive treatment, and increasing dependence on surgery to cure avascular necrosis. According to Bone Therapeutics report in 2017, around 170,000 patients were suffering from avascular necrosis in the U.S., Europe, and Japan. Moreover, side effects from various medicines taken during cancer, HIV/AIDS, osteoporosis, osteoarthritis, blood disorders, or medical treatment such as chemotherapy, radiation therapy, high-dosage of steroids, and organ transplants can increase chances of developing avascular necrosis. However, delay in diagnosis due to asymptomatic nature of this condition at early stage and high cost of surgical treatments for avascular necrosis are the major factors hampering growth of the avascular necrosis market.
This report provides in-depth analysis of the avascular necrosis market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2018 - 2026, considering 2017, as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles key players in the global avascular necrosis market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include Bone Therapeutics, Boehringer Ingelheim GmbH, Bayer AG, Enzo Biochem Inc., Ethicon Inc., Eli Lilly and Company, Grifols SA, Integra LifeSciences Corporation, K-Stemcell Co Ltd., Medtronic Plc, Merck KGaA, Pfizer Inc., Sanofi SA, Stryker Corporation, Wright Medical Group N.V., and Zimmer Biomet Holdings
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global avascular necrosis market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for avascular necrosis products, research and consulting firms, new entrants, and financial analysts
"*" marked represents similar segmentation in other categories in the respective section.